CE, MOC & Certificates

The Genitourinary Cancers Symposium addresses the multidisciplinary needs of physicians and other members of the cancer care and research community who diagnose, treat, and study genitourinary malignancies. The Symposium will explore the latest science and its clinical application, as well as feature keynote lectures from world-renowned experts on the most clinically relevant research across the spectrum of GU cancers. Abstracts with novel and emerging data will be featured in Oral Abstract Sessions, new Rapid Fire Abstract Sessions, and Poster Sessions with networking events.

Accreditation and Designation Statement

In support of improving patient care, the American Society of Clinical Oncology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Society of Clinical Oncology designates this live activity for a maximum of 25.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

All other attendees may request a Certificate of Participation after submitting their session participation. Please note that all final decisions regarding certificate acceptance toward any licensure requirements will be made by the licensing organization to which the certificate is submitted.

Target Audience

This Symposium is designed for physicians and researchers interested in the prevention, screening, evaluation, and management of genitourinary cancers, including, but not limited to medical, surgical, and radiation oncologists; pathologists; radiologists; and other translational-oriented laboratory scientists.

Educational Needs Statement

The 2018 Genitourinary Cancers Symposium – Translating Evidence to Multidisciplinary Care gives healthcare providers across multiple disciplines and professions the opportunity to receive critical updates and recommendations to improve the care of patients with these cancers. Although incidence and mortality rates for many cancers in this area seem difficult to decrease, emerging science offers new options for multidisciplinary precision care through new and emerging diagnostic approaches, as well as innovative therapy options. Continued evolution in the clinical evidence base highlights the ongoing need for education in this area to ensure that all members of the cancer care team can inform themselves in how best to integrate emerging therapies and diagnostic technologies given the options currently available. 

Learning Objectives

Upon participation in this activity, attendees will be able to

  • Collaborate across different specialties and with all members of the oncology care team to provide effective and patient-centered treatment and supportive care for patients with genitourinary cancers;
  • Examine the growing use of immunotherapeutic agents in the treatment of patients with genitourinary cancers, to include both approved clinical indications and ongoing clinical research, and highlight changes for diagnostic approaches as well as changes for treatment decisions and overall patient management;
  • Evaluate and interpret best available current evidence, including recent clinical trials, to inform treatment decisions where multiple therapeutic options exist for a patient with a genitourinary cancer;
  • Outline the genomic tests that are currently available based on existing evidence or in clinical trials, describing the potential impact of biomarkers for diagnosis and therapy selections as well as the potential impact of tumor heterogeneity on treatment decisions and plans for disease monitoring;
  • Discuss the increasing diversity of clinical scenarios where precision imaging can provide diagnostic or prognostic benefit for patients with genitourinary cancers, including use in evaluating indeterminate and post-chemotherapy masses;
  • Describe the optimal uses of hormone therapies in patients with hormone-responsive genitourinary cancers and the accurate interpretation of endocrinology data to manage treatment more effectively.

Disclaimer and Unlabeled Usage Statement

The information presented is that of the contributing faculty and presenters and does not necessarily represent the views of the symposium cosponsors and/or any named company or organization providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty or presenters.  Therefore, before presenting any medication, please review the complete prescribing information including indications, contraindications, warnings, precautions, and adverse effects.